Synergistic effect of posaconazole and caspofungin against clinical zygomycetes [2]

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3457-3458

  Guembe, María ^a   Guinea, Jesús ^a   Peláez, Teresa ^a   Torres Narbona, Marta ^a   Bouza, Emilio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; POSACONAZOLE;

ABSIDIA; ANTIFUNGAL ACTIVITY; CRYPTOCOCCAL MENINGITIS; CUNNINGHAMELLA; DRUG POTENTIATION; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MUCOR; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOMUCOR; RHIZOPUS ORYZAE; SNYCEPHALASTRUM; ZYGOMYCETES;

EID: 35948988436     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00595-07     Document Type: Letter

References (11)

1. Cacciapuoti, A., J. Halpern, C. Mendrick, C. Norris, R. Patel, and D. Loebenberg. 2006. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother. 50:2587-2590.
2. Dannaoui, E., J. Afeltra, J. F. G. M. Meis, P. E. Verweij, and The Eurofung Network. 2002. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob. Agents Chemother. 46:2708-2711.
3. Ibrahim, A. S., J. C. Bowman, V. Avanessian, K. Brown, B. Spellberg, J. E. Edwards, Jr., and C. M. Douglas. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727.
4. Jacobs, P., L. Wood, A. Du Toit, and K. Esterhuizen. 2003. Eradication of invasive mucormycosis. Effectiveness of the echinocandin FK463. Hematology 8:119-123.
5. Mukherjee, P. K., D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194.
6. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
7. Oliveira, E. R., A. W. Fothergill, W. R. Kirkpatrick, B. J. Coco, T. F. Patterson, and S. W. Redding. 2005. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob. Agents Chemother. 49:3544-3545.
8. Richardson, M. D., and G. S. Shankland. 1999. Rhizopus, Rhizomucor, Absidia, and other agents of systemic and subcutaneous zygomycoses, p. 1242-1258. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
9. Spellberg, B., Y. Fu, J. E. Edwards, Jr., and A. S. Ibrahim. 2005. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49:830-832.
10. Torres-Narbona, M., J. Guinea, J. Martínez-Alarcón, T. Peláez, and E. Bouza. 2007. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob. Agents Chemother. 51:1126-1129.
11. Voitl, P., C. Scheibenpflug, T. Weber, O. Janata, and A. M. Rokitansky. 2002. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 21:632-634.